IL33 and neoplasm: By engraftment of tumor tissues from NSCLC patients into immune-deficient mice and subsequent treatment of tumor-bearing mice with IL-33 blockers, we demonstrate that blockade of IL-33 is an efficient strategy to limit NSCLC growth.